Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
Around 7% of the Indian population suffers from IBS
The company had earlier announced about the approval received from the MHRA for Liraglutide
The Cabinet has approved budgetary support of Rs. 2207.50 crore in the 15th Finance Commission Cycle to run CAPFIMS as a campus of AIIMS, New Delhi.
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
The product will be launched in March 2024
Both the Ministries signed MoU for anaemia control among adolescent girls using Ayurveda interventions
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
Subscribe To Our Newsletter & Stay Updated
